$30.73
0.49%
Nasdaq, Sep 24, 04:00 pm EDT. Closed.
ISIN
US9183851057
Symbol
VTVT

vTv Therapeutics, Inc. Class A Stock price

$30.73
-3.16 9.32% 1M
-5.48 15.13% 6M
-9.26 23.16% YTD
+8.56 38.58% 1Y
+12.73 70.68% 3Y
-42.47 58.02% 5Y
-258.47 89.37% 10Y
-404.87 92.95% 20Y
Nasdaq, Closing price Thu, Sep 24 2026
+0.15 0.49%
ISIN
US9183851057
Symbol
VTVT
Industry

Is vTv Therapeutics, Inc. Class A a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,127 stocks worldwide.

Key metrics

Basic
Market capitalization
$124.4m
Enterprise Value
$37.7m
Net debt
positive
Cash
$86.6m
Shares outstanding
3.9m
Valuation (TTM | estimate)
P/E
negative
P/S
3.4 | 4.1
EV/Sales
1.0 | 1.2
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
71.7%
Return on Equity
-41.9%
ROCE
-11.5%
ROIC
152.4%
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$36.8m | $30.4m
EBITDA
$-9.3m
EBIT
$-9.3m
Net Income
$-4.8m
Free Cash Flow
$-16.8m
Growth (TTM | estimate)
Revenue
184,100.0% | -
EBITDA
63.8%
EBIT
63.9%
Net Income
75.7%
Free Cash Flow
23.9%
Margin
Gross
-
EBITDA
-25.1%
EBIT
-25.1%
Net
-12.9%
Free Cash Flow
-45.5%
More
EPS
$-0.4
FCF per Share
$-4.3
Short interest
6.8%
Employees
26
Rev per Employee
$0.0

vTv Therapeutics, Inc. Class A Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a vTv Therapeutics, Inc. Class A forecast:

Buy
91%
Hold
9%

Financial data from vTv Therapeutics, Inc. Class A

Jun '26
+/-
%
37 37
184,100% 184,100%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 17 17
31% 31%
47%
- Research and Development Expense 29 29
131% 131%
78%
-9.25 -9.25
64% 64%
-25%
- Depreciation and Amortization 0.01 0.01
83% 83%
0%
EBIT (Operating Income) EBIT -9.25 -9.25
64% 64%
-25%
Net Profit -4.76 -4.76
76% 76%
-13%

In millions USD.

Don't miss a Thing! We will send you all news about vTv Therapeutics, Inc. Class A directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

vTv Therapeutics, Inc. Class A Stock News

Neutral
GlobeNewsWire
●
10 days ago
HIGH POINT, N.C., Sept. 15, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to ...
Neutral
GlobeNewsWire
●
about one month ago
HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a...
Neutral
GlobeNewsWire
●
about 2 months ago
Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the...
More vTv Therapeutics, Inc. Class A News

Company Profile

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Head office United States
CEO Mr. Sekhri
Employees 26
Founded 2015
Website vtvtherapeutics.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today